Category: Regulatory

What is an IND Application (Investigational New Drug Application) In the pharmaceutical industry, new drugs must undergo rigorous evaluation before they can be tested in humans. One of the most important regulatory steps in this process is the Investigational New Drug Application (IND). The IND allows pharmaceutical companies to begin clinical trials and ensures that… Continue reading What is an IND Application (Investigational New Drug Application)

Responding to FDA Form 483 Observations After a Drug CGMP Inspection Regulatory checks are very essential in the aspect of making sure that pharmaceutical producers are adhering to the existing requirements of Good Manufacturing Practice (CGMP). In an inspection, U.S. Food and drug administration (FDA) might find conditions that may be against regulatory provisions. Such… Continue reading How to Respond to FDA Form 483 Observations After a Drug CGMP Inspection

Understanding the FDA Draft Guidance on Biosimilar Development and the BPCI Act (Revision 4) The U.S. Food and Drug Administration (FDA) released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) in March 2026 to clarify regulatory expectations for biosimilar and interchangeable biological products.

What is Quality by Design (QbD) in Regulatory Affairs? Quality by Design (QbD) in Regulatory Affairs is a systematic, science-based approach to pharmaceutical development that focuses on building quality into a product from the earliest stages rather than testing it at the end.

What is a Pre-IND Meeting for US FDA? A Pre-IND meeting for the US FDA is a formal meeting between a drug sponsor and the U.S. Food and Drug Administration (FDA) that takes place before submitting an Investigational New Drug (IND) application. The purpose of this meeting is to obtain regulatory guidance on the planned… Continue reading What is a Pre-IND Meeting for US FDA?

What is a Public Assessment Report (PAR)? A Public Assessment Report (PAR) is an official regulatory document that provides a scientific summary of the evaluation of a medicinal product after it has been approved. It explains how a regulatory authority assessed the quality, safety, and efficacy of a product before granting marketing authorization. The PAR… Continue reading What is a Public Assessment Report (PAR)?

What Is an INAD (Investigational New Animal Drug)? Investigational New Animal Drug (INAD) is an important aspect in the pharmaceutical and veterinary regulatory environment that facilitates the transfer of innovative animal health products out of the laboratory into the market. An INAD is a regulatory filing by the U.S. Food and Drug Administration (FDA) (via… Continue reading What Is an INAD (Investigational New Animal Drug)?

What is RMP (Risk Management Plan)? In the pharmaceutical industry, patient safety is a constant task that extends well beyond clinical development and initial marketing approval. Pharmacovigilance documentation that is arranged methodically and outlines how potential and identified risks of a medication are managed and controlled over the course of its lifecycle is called a… Continue reading What is RMP (Risk Management Plan)?

What Is Clinical Data Management (CDM)? In the pharmaceutical sector, Clinical Data Management (CDM) is crucial for guaranteeing that the data gathered during clinical trials is accurate, dependable, and compliant with regulatory requirements.

What is Regulatory Intelligence? Regulatory Intelligence (RI) in the pharmaceutical sector is more than just monitoring the latest regulations. It’s about interpreting what those regulations mean, foreseeing changes, and applying that understanding to navigate drug development and compliance effectively.